Drug Trial Radar · NCT04768972
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
89
Actual
Start
Jun 14, 2021
Primary completion
Jun 17, 2026
Study completion Mar 2028
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Feb 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
ION363Drug
ION363 will be administered by IT bolus injection.
PlaceboDrug
Placebo will be administered by IT bolus injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline (Day 1) through Study Day 505 in Part 1 in functional impairmentTime frame: Baseline, Day 505 in Part 1
Locations
25 sites in 16 countries. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Stanford University Medical Center
Palo Alto, California
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center
New York, New York
The Ohio State University Wexner Medical Center
Columbus, Ohio
University of Utah
Salt Lake City, Utah
UZ Leuven
Leuven, VL-Brabant, Belgium
PSEG Centro de Pesquisa Clinica S.A.
São Paulo, Brazil
Montreal Neurological Institute
Montreal, Quebec, Canada
Universitaetsmedizin Rostock
Rostock, Germany
Universitätsklinikum Ulm
Ulm, Germany
St. James Hospital
Dublin, Ireland
Citta della Salute e della Scienza di Torino - Ospedale le Molinette
Torino, Italy
Toho University Omori Medical Center
Tokyo, Japan
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Linden spólka z ograniczona odpowiedzialnoscia spólka komandytow
Krakow, Poland
Seoul National University Hospital
Seoul, South Korea
Hanyang University Seoul Hospital
Seoul, South Korea
Hospital Universitari de Bellvitge
Barcelona, Spain
University Hospital of Umea
Umeå, Sweden
Kantonsspital St. Gallen
Sankt Gallen, Switzerland
Taipei Veterans General Hospital (VGHTP)
Taipei, Taiwan
King's College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.